Last-Hope cancer drug tested in real patients
NCT ID NCT02310477
Summary
This study followed 704 patients with metastatic colorectal cancer who had run out of other treatment options. They received the drug regorafenib through a special French access program. Researchers tracked how long patients lived, how they tolerated the drug, and how it performed outside of strict clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Oscar Lambret
Lille, 59020, France
Conditions
Explore the condition pages connected to this study.